论文部分内容阅读
肺癌的发病率近年一直呈上升趋势,仅美国每年就有161000例新发现的肺癌,其中80％为非小细胞肺癌(NSCLC)。NSCLC的预后差,总5年存活率只有14％。疗效好坏与接受治疗时的TNM分期密切相关。早期肺癌的公认治疗方法为手术切除,疗效可达50％～70％。但初诊时有50％以上的患者处在Ⅲ、Ⅳ期,即已有胸内淋巴结的转移与受累,甚或有远处转移。对这些患者的治疗选择一直存在争议。本文就近期国外的文献作一综述。
The incidence of lung cancer has been on an upward trend in recent years. In the United States alone, there are 161,000 newly discovered lung cancers each year, of which 80% are non-small cell lung cancer (NSCLC). The prognosis of NSCLC is poor and the total 5-year survival rate is only 14%. The efficacy is closely related to the TNM stage at the time of treatment. The accepted treatment for early stage lung cancer is surgical resection, with an efficacy of 50% to 70%. However, at the time of initial diagnosis, more than 50% of the patients were in stage III and IV, ie, there had been metastases and involvement of intrathoracic lymph nodes, or even distant metastases. The choice of treatment for these patients has been controversial. This article reviews recent foreign literature.